What All Of Them Are Telling Concerning Erlotinib Is Truly All False And The Actual Reason Why

49% pts had received rituximab in combination with chemotherapy and 13(16%) in the maintenance. The effect of such "" soft treatment"" was high and did not yield the results of first line treatment: second OR was 81%(CR-31%). The median duration of second remission was 45 months. 5-ys overall survival (OS) in all 156 patients was 91%, 10-ys OS - 83%. In 84 patients with relapsed, only 19(23%) previously received rituximab and only 7(8%) had immunochemotherapy followed by rituximab maintenance. Conclusion: The introduction of rituximab in treatment of FL helped to keep the tumor without additional toxicity. Satisfactory results of relapse treatment associated with rituximab high efficiency in FL, especially in pts did not received it earlier. 368 SPLENIC MARGINAL ZONE B-CELL LYMPHOMA: COURSE AND TREATMENT E. Verrou, T. Dimou, N. Spyridis, K. Pentidou, E. Giannopoulou, A. Papadopoulou, http://www.selleckchem.com/products/MK-2206.html S. Papadaki, P. Konstantinidou. Hematology-Oncology, Theagenion Cancer Center, Thessaloniki, Greece Introduction: Splenicmarginalzone B-cell lymphoma (SMZL) is an indolent lymphoma, presenting with splenic enlargement and generally associated with bone marrow infiltration. The optima lmanagement of SMZL is controversial. Methods: We retrospectively studied the cases http://www.selleck.cn/products/Erlotinib-Hydrochloride.html of 15 patients (9 male/6 female) with SMZL with median age 66 years (range: 46-77). Results: All patients presented with splenomegaly. Anemia (Hb http://www.selleckchem.com/products/ABT-263.html with rituximab, 1 received rituximab combined chemotherapy (CVP), 2 received chlorambucil and one fludarabine. Finally one patient remained in observation. Overall response rate to treatment options was 93.3%. Complete response was observed in 10 patients (66.6%) and partial response in four patients (26.6%) while one patient had progressive disease. The median overall survival (OS) was 68 months (range 6-187) with five- year OS 100% while the median failure free survival (FFS) was 22 months (range 1-173) with five-year FFS 66.9 +/- 14.2%. Conclusions:SMZL have an indolent course and show high rates of response to therapy. The optimal management remains to be defined. 368 bis NODAL FOLLICULAR LYMPHOMA IN THE INDIAN CONTEXT A. Ananthamurthy, D. Supari.